Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

610 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.
Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, Datir R, Collier DA, Albecka A, Singh S, Pandey R, Brown J, Zhou J, Goonawardane N, Mishra S, Whittaker C, Mellan T, Marwal R, Datta M, Sengupta S, Ponnusamy K, Radhakrishnan VS, Abdullahi A, Charles O, Chattopadhyay P, Devi P, Caputo D, Peacock T, Wattal C, Goel N, Satwik A, Vaishya R, Agarwal M; Indian SARS-CoV-2 Genomics Consortium (INSACOG); Genotype to Phenotype Japan (G2P-Japan) Consortium; CITIID-NIHR BioResource COVID-19 Collaboration; Mavousian A, Lee JH, Bassi J, Silacci-Fegni C, Saliba C, Pinto D, Irie T, Yoshida I, Hamilton WL, Sato K, Bhatt S, Flaxman S, James LC, Corti D, Piccoli L, Barclay WS, Rakshit P, Agrawal A, Gupta RK. Mlcochova P, et al. Among authors: yoshida i. Nature. 2021 Nov;599(7883):114-119. doi: 10.1038/s41586-021-03944-y. Epub 2021 Sep 6. Nature. 2021. PMID: 34488225 Free PMC article.
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M; Genotype to Phenotype Japan (G2P-Japan) Consortium; Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K. Saito A, et al. Among authors: yoshida i. Nature. 2022 Feb;602(7896):300-306. doi: 10.1038/s41586-021-04266-9. Epub 2021 Nov 25. Nature. 2022. PMID: 34823256 Free PMC article.
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, Morioka Y, Nao N, Nasser H, Uriu K, Kosugi Y, Tsuda M, Orba Y, Sasaki M, Shimizu R, Kawabata R, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sawa H, Ikeda T, Irie T, Matsuno K, Tanaka S, Fukuhara T, Sato K. Suzuki R, et al. Nature. 2022 Mar;603(7902):700-705. doi: 10.1038/s41586-022-04462-1. Epub 2022 Feb 1. Nature. 2022. PMID: 35104835 Free PMC article.
Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection.
Uriu K, Cárdenas P, Muñoz E, Barragan V, Kosugi Y, Shirakawa K, Takaori-Kondo A; Ecuador-COVID19 Consortium, The Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato K. Uriu K, et al. J Infect Dis. 2022 Sep 28;226(7):1200-1203. doi: 10.1093/infdis/jiac053. J Infect Dis. 2022. PMID: 35176774 Free PMC article.
Characteristics of SARS-CoV-2 Isolated from Asymptomatic Carriers in Tokyo.
Nagashima M, Kumagai R, Yoshida I, Kawakami M, Nagano M, Asakura H, Kaku E, Kitamura Y, Hasegawa M, Hayashi Y, Chiba T, Sadamasu K, Yoshimura K. Nagashima M, et al. Among authors: yoshida i. Jpn J Infect Dis. 2020 Jul 22;73(4):320-322. doi: 10.7883/yoken.JJID.2020.137. Epub 2020 Apr 30. Jpn J Infect Dis. 2020. PMID: 32350227 Free article. No abstract available.
Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
Ueno M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, Saito S, Ashida S, Yoshida I, Nagashima M, Asakura H, Yaoita Y, Suzuki J, Sadamasu K, Yoshimura K, Kutsuna S, Shiwa-Sudo N, Nagata N, Suzuki T, Suzuki A, Okamoto M, Kimura M, Ohmagari N, Miura R, Ishizaka Y. Ueno M, et al. Among authors: yoshida i. Antiviral Res. 2022 May;201:105297. doi: 10.1016/j.antiviral.2022.105297. Epub 2022 Mar 24. Antiviral Res. 2022. PMID: 35341809 Free PMC article.
Does the SARS-CoV-2 rapid antigen test result correlate with the viral culture result?
Yamamoto K, Nagashima M, Yoshida I, Sadamasu K, Kurokawa M, Nagashima M, Kinoshita N, Maeda K, Takasaki J, Teruya K, Ohmagari N. Yamamoto K, et al. Among authors: yoshida i. J Infect Chemother. 2021 Aug;27(8):1273-1275. doi: 10.1016/j.jiac.2021.05.006. Epub 2021 May 12. J Infect Chemother. 2021. PMID: 34023222 Free PMC article.
RNA Detection Using RT-qPCR and Non-Isolation of SARS-CoV-2 in Concentrated Wastewater (June-August 2020, Tokyo).
Nagashima M, Kawakami M, Hayashi M, Kumagai R, Kasuya F, Yoshida I, Kashihara N, Morita K, Yamada K, Fujiwara T, Kitamura K, Yoshida H, Chiba T, Sadamasu K. Nagashima M, et al. Among authors: yoshida i, yoshida h. Jpn J Infect Dis. 2022 Mar 24;75(2):212-215. doi: 10.7883/yoken.JJID.2021.055. Epub 2021 Oct 29. Jpn J Infect Dis. 2022. PMID: 34719528 Free article. No abstract available.
610 results